Clinical trials: Malaria (Plasmodium Falciparum)
Malaria (Plasmodium Falciparum), Malaria Incidence
Permethrin-Treated Baby Wraps for Malaria Prevention in Refugee Settings
The objective is to test the protective effect of permethrin-treated lesus against malaria in young children in refugee settings
- Trial name
- NCT07903324
- Testing
- Factory-treated lesu, Soaked lesu, Untreated lesu
- Where
- Uganda
- Volunteers
- 1,350 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)
This was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07811908)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 13 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Malaria Vaccines, Malaria (Plasmodium Falciparum)
Infant Malaria Vaccine Schedule Optimization
The aim of this study is to identify an optimal infant vaccine schedule for a malaria vaccine which is better aligned with the timing of other vaccine interventions.
- Trial name
- NCT06879327
- Testing
- R21 Matrix-M (R21/MM) Malaria Vaccine, Hexavalent Vaccine, Pneumococcal Polysaccharide Conjugate Vaccine
- Where
- 2 sites in Burkina Faso
- Volunteers
- 975 people, healthy volunteers welcome
- Sponsor
- PATH
Plasmodium Vivax Malaria Without Complication, Plasmodium Falciparum Malaria (Uncomplicated)
Ethiopian Antimalarial Therapeutic Efficacy Study 2026
Background: The WHO recommends monitoring the efficacy of antimalarial drugs at least once every two years after implementation.
- Trial name
- TES2026 (NCT07840898)
- Testing
- Artemether-Lumefantrine + Primaquine and Chloroquine + Primaquine
- Where
- Ethiopia
- Volunteers
- 1,200 people
- Sponsor
- Ethiopian Public Health Institute
Uncomplicated Plasmodium Falciparum Malaria
Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial
Background: Artemisinin resistance has emerged in parts of Southeast Asia, and there are reports in Africa of reduced susceptibility of Plasmodium falciparum parasites against artemisinin-based combination therapy (ACT).
- Trial name
- 3ACT (NCT05764746)
- Testing
- Artemether-lumefantrine and Amodiaquine Drug Combination, Artemether-lumefantrine then Artesunate amodiaquine, Artemether-lumefantrine
- Where
- 2 sites in Tanzania
- Volunteers
- 384 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Malaria Vivax, Malaria Falciparum
Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar
The resilience of P. vivax to malaria elimination efforts is due to its ability to form dormant liver stages (hypnozoites) that reactivate weeks to months after the initial infection causing recurrent episodes of malaria…
- Conditions
- Malaria Vivax, Malaria Falciparum, Plasmodium Vivax, Plasmodium Falciparum
- Trial name
- PvSTATEM (NCT06923592)
- Testing
- PvSeroTAT, Control
- Where
- 2 sites in Ethiopia, Madagascar
- Volunteers
- 19,200 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Plasmodium Falciparum Malaria, Pregnancy Malaria
Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women in Papua New Guinea
Malaria during pregnancy remains an important public health issue in endemic countries. Most cases of malaria in pregnant women are asymptomatic, and can contribute to adverse outcomes, such as maternal and neonatal anaemia as…
- Conditions
- Plasmodium Falciparum Malaria, Pregnancy Malaria, Diagnoses Disease
- Trial name
- NCT03462615
- Testing
- HS-RDT
- Where
- Papua New Guinea
- Volunteers
- 930 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Malaria (Plasmodium Falciparum)
Controlled Human Malaria Infection by Mosquito Bites Using a Local Strain of Plasmodium Falciparum
The project aims to reproduce the malaria infection cycle using African mosquitoes, namely Anopheles gambiae and a local strain of Plasmodium parasites.
- Trial name
- BB-LaCHMI-01 (NCT07816497)
- Testing
- Controlled Human Malaria Infection
- Where
- Gabon
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)
This is Cohort B1 of the Platform study (NCT05750628) to evaluate the efficacy and safety of INE963 + Cipargamin in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07811882)
- Testing
- KAE609 (Cipargamin), SoC (Coartem), INE963
- Where
- 13 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Malaria (Plasmodium Falciparum)
Malaria CVD 36000; Gates INV090205
In order to control infections, the investigators must first detect them. Biosensor devices may allow early detection and intervention for infectious diseases, helping the investigators to recognize infections early, and allow…
- Trial name
- NCT07558122
- Testing
- PfSPZ Challenge (NF54), Wearable Biosensor Devices
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Malaria (Plasmodium Falciparum)
Dose Finding Trial of R21/Matrix-M in School Children
This trial is a double-blind, randomised, trial recruiting participants from the R21 phase IIb trial (VAC 076) which took place between May 2019 and July 2023 in Nanoro, Burkina Faso.
- Trial name
- NCT07074665
- Testing
- 5µg R21/50µg Matrix-M, 10µg R21/50µg Matrix-M
- Where
- Burkina Faso
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria (Plasmodium Falciparum), Malaria Incidence
Insecticide-Treated Baby Wraps for the Prevention of Malaria
The objective is to test the protective effect of permethrin-treated and etofenprox-treated lesus against malaria in young children
- Trial name
- NCT07773350
- Testing
- Permethrin-treated lesu, Etofenprox-treated lesu, Untreated lesu
- Where
- Uganda
- Volunteers
- 1,296 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Malaria, Plasmodium Falciparum
A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK
This is an open label, single-site, first-in-human, dose-escalation Phase Ia study to assess safety and immunogenicity of the Plasmodium falciparum malaria vaccine candidate Pfs48/45 in Matrix-M adjuvant in healthy adults living…
- Trial name
- NCT05400746
- Testing
- Pfs48/45 in Matrix-M
- Where
- United Kingdom
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, PLASMODIUM FALCIPARUM MALARIA
Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT)
The AVERT study is a prospective observational test-negative case control study evaluating the real-world effectiveness of the R21/Matrix-M malaria vaccine among children younger than 5 years in Burkina Faso and Uganda.
- Trial name
- AVERT (NCT07749911)
- Testing
- R21/Matris-M Malaria vaccine
- Where
- 21 sites in Burkina Faso, Uganda
- Volunteers
- 20,000 people
- Sponsor
- Clinton Health Access Initiative Inc.
Plasmodium Falciparum Malaria, Malaria
R21/MM Dosing, Presentations, and Preservatives
This is a single blind randomised controlled trial (Phase 3 trial). This study aims to assess whether a half-dose of the R21/Matrix-M malaria vaccine is as effective as the full dose in children and adults.
- Conditions
- Plasmodium Falciparum Malaria, Malaria, Vaccine Reaction
- Trial name
- VAC100 (NCT07194668)
- Testing
- 10μg R21/50μg Matrix-M, 5μg R21/50μg Matrix-M with adaptor preservative free, 5μg R21/50μg Matrix-M with 2PE preservative
- Where
- 2 sites in Bangladesh
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria (Plasmodium Falciparum)
Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
This is a randomized, double-blind, placebo-controlled, Phase 1 trial of Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) malaria vaccine (Sanaria® PfSPZ-LARC2 Vaccine)…
- Trial name
- BFSPZL3 (NCT07730177)
- Testing
- PfSPZ-LARC2 Vaccine, PfSPZ Challenge, Normal Saline
- Where
- Burkina Faso
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria (Plasmodium Falciparum)
PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali
A randomized double blind, placebo-controlled study to assess the safety, tolerability, immunogenicity, and protective efficacy of 1, 6, 29-day PfSPZ-LARC2 Vaccine regimen given at a dose of 2 x10^5 PfSPZ or placebo in healthy…
- Trial name
- NCT07675785
- Testing
- PfSPZ-LARC2 Vaccine, Normal Saline
- Where
- Mali
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria (Plasmodium Falciparum)
Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria
This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL).
- Trial name
- NCT07559370
- Testing
- Artemether lumefantrine tablets, Artemether Lumefantrine and Imatinib Mesylate
- Where
- Kenya
- Volunteers
- 1,116 people
- Sponsor
- Victoria Biomedical Research Institute
Plasmodium Falciparum Infection
Pharmacokinetic Study of IV Artesunate to Treat Children With Severe Malaria
This clinical study is a phase 4, single-site, open-label pharmacokinetic (PK) study of IV artesunate in up to 100 Ugandan children 6 months-14 years of age who are diagnosed with severe malaria according to standardized World…
- Trial name
- NCT05750459
- Testing
- Artesunate
- Where
- Uganda
- Volunteers
- 90 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria (Plasmodium Falciparum)
Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults
This is a phase 2 clinical trial of a Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) vaccine (Sanaria® PfSPZ-LARC2 Vaccine) that will assess field efficacy in Africa.
- Trial name
- BFSPZL2 (NCT07385287)
- Testing
- Genetically attenuated PfSPZ Vaccine, Normal Saline (0.9% Sodium Chloride)
- Where
- Burkina Faso
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.